Management of luspatercept therapy in patients with transfusion-dependent ß-thalassaemia.
Br J Haematol
; 201(5): 824-831, 2023 06.
Article
en En
| MEDLINE
| ID: mdl-37037668
ABSTRACT
Patients with transfusion-dependent ß-thalassaemia require lifelong, regular red blood cell transfusions for survival; however, frequent blood transfusions are associated with an increased risk of iron overload, transfusion-transmitted disease and alloimmunization, as well as reduced quality of life. Luspatercept, an erythroid maturation agent that promotes late-stage erythroid maturation independently of erythropoietin, has demonstrated efficacy in reducing transfusion burden in patients with transfusion-dependent ß-thalassaemia. In this review, we discuss treatment initiation, ongoing evaluation, dose adjustment and management of adverse events in transfusion-dependent patients with ß-thalassaemia receiving luspatercept, and we provide guidance on how to determine whether patients are deriving clinical benefit.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Fragmentos Fc de Inmunoglobulinas
/
Talasemia beta
/
Factores Inmunológicos
Tipo de estudio:
Etiology_studies
/
Guideline
Límite:
Humans
Idioma:
En
Revista:
Br J Haematol
Año:
2023
Tipo del documento:
Article
País de afiliación:
Estados Unidos